Sequel, Senseonics announce full launch of CGM, pump pairing
Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration.
Sequel Med Tech and Senseonics announced full availability of the twiist automated insulin delivery (AID) system integrated with the Eversense 365 continuous glucose monitoring ( CGM ) system in the U.S. Powered by Tidepool, twiist is touted as the first AID system compatible with Eversense 365, a one-year CGM .
Sequel, Senseonics announce full launch of Eversense 365 CGM, twiist ...
Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. Manchester, New Hampshire-based Sequel and Germantown, Maryland-based Senseonics now offer the Eversense 365 continuous glucose monitor ( CGM ) with the twiist automated insulin delivery (AID) system for people with type 1 diabetes in the U.S.
Sequel Med Tech and Senseonics announced full U.S. availability of the twiist Automated Insulin Delivery System integrated with the Eversense 365 CGM , the wo...
Sequel Med Tech and Senseonics Launch Transformative Combination of ...
MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on long-term, implantable Continuous Glucose Monitoring ( CGM ) systems for people with diabetes, today announced full availability of the twiist ...
[Images courtesy of Sequel Med Tech and Senseonics ] Senseonics (NYSE:SENS) announced today that it began the launch of its Eversense 365 sensor with the Sequel Med Tech twiist pump . The companies said today that the first commercial patients have now received their paired continuous glucose monitor ( CGM ) and automated insulin delivery (AID) system.
SENS Press Release
Globe Newswire 19-Feb-2026 8:00 AM MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on long-term, implantable Continuous Glucose Monitoring ( CGM ) systems for people with diabetes, today announced full ...
This powerful combination is a significant leap forward for the diabetes community, offering a transformative solution for long-term diabetes management by significantly reducing the burden of frequent sensor changes and re- pairing while maintaining exceptional CGM accuracy.
Sequel Med Tech
MANCHESTER, NH and GERMANTOWN, MD— February 19, 2026 — Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on long-term, implantable Continuous Glucose Monitoring ( CGM ) systems for people with diabetes, today announced full ...
Any statements in this press release about future expectations, plans and prospects for Senseonics , including the integration of the Sequel twiist AID system paired with the Eversense 365 CGM , statements regarding the potential benefits and accuracy related to using the Sequel twiist AID system paired with the Eversense 365 CGM and the broad ...